A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
NCT ID: NCT04948554
Last Updated: 2023-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
5 participants
INTERVENTIONAL
2023-03-10
2023-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: MK-2225
Participants in Cohort 1 will receive MK-2225 at 0.25 mg/kg once every two weeks (Q2W) plus standard of care (SOC) for 12 weeks.
MK-2225
Administered Subcutaneously (SC)
Cohort 1: Placebo
Participants in Cohort 1 will receive placebo Q2W plus SOC for 12 weeks.
Placebo
Administered SC
Cohort 2: MK-2225
Participants in Cohort 2 will receive MK-2225 at 0.5 mg/kg (or lower) Q2W plus SOC for 12 weeks.
MK-2225
Administered Subcutaneously (SC)
Cohort 2: Placebo
Participants in Cohort 2 will receive placebo Q2W plus SOC for 12 weeks.
Placebo
Administered SC
Cohort 3: MK-2225
Participants in Cohort 3 will receive MK-2225 at 1.0 mg/kg (or lower) Q2W plus SOC for 12 weeks.
MK-2225
Administered Subcutaneously (SC)
Cohort 3: Placebo
Participants in Cohort 3 will receive placebo Q2W plus SOC for 12 weeks.
Placebo
Administered SC
Cohort 4: MK-2225
Participants in Cohort 4 will receive MK-2225 at ≤2.0 mg/kg Q2W if needed plus SOC for 12 weeks.
MK-2225
Administered Subcutaneously (SC)
Cohort 4: Placebo
Participants in Cohort 4 will receive placebo Q2W plus SOC for 12 weeks.
Placebo
Administered SC
Cohort 5: MK-2225
Participants in Cohort 5 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
MK-2225
Administered Subcutaneously (SC)
Cohort 5: Placebo
Participants in Cohort 5 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
Placebo
Administered SC
Cohort 6: MK-2225
Participants in Cohort 6 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
MK-2225
Administered Subcutaneously (SC)
Cohort 6: Placebo
Participants in Cohort 6 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK-2225
Administered Subcutaneously (SC)
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* If participant is on a non-excluded immunosuppressive therapy (e.g. mycophenolate, methotrexate, azathioprine, etc.) the dose should be stable for \> 2 months at the time of screening
* Women of childbearing potential must:
* If sexually active, have used, and agree to use, highly effective contraception without interruption, for at least 28 days prior to starting investigational product, during the study (including dose interruptions), and for 17 weeks (119 days) after discontinuation of study treatment
* Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 17 weeks (119 days) after the last dose of study treatment
* Male participants must:
* Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 17 weeks (119 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
* Refrain from donating blood or sperm for the duration of the study and for 17 weeks (119 days) after the last dose of study treatment
* Must agree to not participate in any other study of investigational drugs/devices while enrolled in this study
Exclusion Criteria
* In the opinion of the investigator, other clinically significant pulmonary abnormalities (such as obstructive lung disease, asthma, etc.)
* Other investigational therapy received within 1 month or 6 half-lives (whichever is greater) prior to the Screening Visit
* Prior exposure to MK-2225 or other TGF-β antibodies or any TGF-β family targeted biologic or hypersensitivity to the components of MK-2225
* Hypersensitivity to placebo or any of its components
* Previous hematopoietic stem cell transplantation (HSCT) or HSCT planned within the next year
* Major surgical procedures planned during the study period
* Oral prednisone or equivalent \> 10 mg/day
* Participant with history of gastric antral vascular ectasia or gastrointestinal bleed
* On anticoagulation therapy (such as prophylaxis anticoagulation, warfarin, direct thrombin inhibitors or other including low molecular weight subcutaneous or intravenous therapeutic heparin), or antiplatelet therapy including aspirin. Use of fish oil supplements within 2 weeks prior to randomization and throughout study is not permitted.
* History of any other medical condition that might interfere with a participant's ability to participate in the study
* Active clinically significant viral, bacterial, or fungal infection, or any episode of infection requiring hospitalization within 4 weeks prior to screening
* Use of cyclophosphamide ≤ 6 months from screening
* Use of nintedanib or pirfenidone ≤ 28 days from screening
* Recent scleroderma renal crisis \< 6 months before screening
* Use of tocilizumab ≤ 2 months from screening
* Has received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention. Exception: COVID-19 vaccine may be administered.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Altman Clinical and Translational Research Institute (Site 1013)
La Jolla, California, United States
Keck Medical Center ( Site 1001)
Los Angeles, California, United States
Georgetown University Medical Center ( Site 1010)
Washington D.C., District of Columbia, United States
University of Florida ( Site 1002)
Gainesville, Florida, United States
Central Florida Pulmonary Group ( Site 1005)
Orlando, Florida, United States
Medster Research, LLC ( Site 1017)
Valdosta, Georgia, United States
University of Kansas Medical Center ( Site 1007)
Kansas City, Kansas, United States
The Cleveland Clinic Foundation ( Site 1003)
Cleveland, Ohio, United States
Penn State Milton S Hershey Medical Center ( Site 1004)
Hershey, Pennsylvania, United States
West Tennessee Research Institute ( Site 1012)
Jackson, Tennessee, United States
Metroplex Clinical Research Center ( Site 1018)
Dallas, Texas, United States
Mount Sinai Hospital ( Site 1101)
Toronto, Ontario, Canada
Azienda Ospedaliero Universitaria Careggi (Site 1401)
Florence, Tuscany, Italy
Azienda Ospedaliera Universitaria Integrata Di Verona ( Site 1402)
Verona, Veneto, Italy
Kantonsspital St. Gallen (Site 1301)
Sankt Gallen, Canton of St. Gallen, Switzerland
Hôpital Neuchatelois ( Site 1304)
Neuchâtel, Neuchâtel (fr), Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1334-02
Identifier Type: OTHER
Identifier Source: secondary_id
MK-2225-002
Identifier Type: OTHER
Identifier Source: secondary_id
2021-001004-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2225-002
Identifier Type: -
Identifier Source: org_study_id